The Food and Drug Administration (FDA) on Wednesday confirmed there is an Adderall shortage in the United States amid reports of people having prescriptions for the ADHD drug.
The FDA “is in frequent communication with all manufacturers of amphetamine mixed salts, and one of those companies, Teva, is experiencing ongoing intermittent manufacturing delays,” a statement from the agency said, referring to precursors to manufacture Adderall—a drug mixture composed of equal parts racemic amphetamine and dextroamphetamine.
According to the FDA’s website, supply recovery for different doses and forms of the drug ranges from October 2022 to March 2023.
“Until supply is restored, there are alternative therapies including the extended-release version of amphetamine mixed salts available to health care professionals and their patients for amphetamine mixed salts’ approved indications,” the FDA’s continued. “Patients should work with their health care professionals to determine their best treatment option.”…